RAPPORT THERAPEUTICS INC (RAPP) competitors & alternatives
Health Care · NASDAQ
RAPPORT THERAPEUTICS INC (RAPP)'s top competitors and alternatives — its most similar public companies — include PRELUDE THERAPEUTICS INC (PRLD), REZOLUTE INC (RZLT), CULLINAN THERAPEUTICS INC (CGEM), MAPLIGHT THERAPEUTICS INC (MPLT), AVALYN PHARMA INC (AVLN), MONOPAR THERAPEUTICS INC (MNPR), ELEDON PHARMACEUTICALS INC (ELDN), NEUMORA THERAPEUTICS INC (NMRA), MONTE ROSA THERAPEUTICS INC (GLUE), NURIX THERAPEUTICS INC (NRIX), RECURSION PHARMACEUTICALS INC CLAS (RXRX) and PTC THERAPEUTICS INC (PTCT). These are RAPPORT THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top RAPP competitors & alternatives
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
-
MAPLIGHT THERAPEUTICS INCMPLTHealth Care
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, targeted treatments for central nervous…
$35.31 (as of 2026-07-22) · market cap $1.6B
-
AVALYN PHARMA INCAVLNHealth Care
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases.
$28.72 (as of 2026-07-22) · market cap $1.3B
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$112.48 (as of 2026-07-22) · market cap $752M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
NEUMORA THERAPEUTICS INCNMRAHealth Care
Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
$1.54 (as of 2026-07-22) · market cap $298M
-
MONTE ROSA THERAPEUTICS INCGLUEHealth Care
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its…
$23.79 (as of 2026-07-22) · market cap $2.0B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
RECURSION PHARMACEUTICALS INC CLASRXRXHealth Care
Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug…
$2.98 (as of 2026-07-22) · market cap $1.6B
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
Not quite? Describe exactly what you want →
Peers are RAPPORT THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: RAPPORT THERAPEUTICS INC (RAPP).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.